Vandetanib approved for metastatic medullary thyroid cancer

Links shared publicly online about this topic.

  • 384
    total visits

Vandetanib approved for metastatic medullary thyroid cancer

endocrinetoday.com

The FDA announced approval of vandetanib for adults with metastatic medullary thyroid cancer who are ineligible for surgery and have disease that

View full resource at endocrinetoday.com

Tags: Cancer, Thyroid Cancer, Medullary Thyroid Cancer, Disease and Condition, FDA, Surgery, disease

  • Share

Most Recently Shared on April 7, 2011 at 8:08 am By:

NatureRevEndo NatureRevEndocrinol

RT @endocrinetoday: Vandetanib approved for metastatic medullary thyroid cancer http://bit.ly/hGRg7G

1 year ago...

Also Shared By:

Endocrine Today Endocrine Today

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial - OncologySTAT

oncologystat.com — “2011 Oct 24;[Epub Ahead of Print] - SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, E Baudin, R Elisei, B Jarzab, JR Vasselli, J Read, P Langmuir, AJ Ryan, MJ SchlumbergerView full resource at oncologystat.com

  • View Related
  • Share

Most Recently Shared on November 3, 2011 at 5:24 pm By:

oncologystat OncologySTAT Oncology and Health Site

Story of the Week: Vandetanib Effective in Advanced Medullary Thyroid Cancer http://t.co/CA1KGTDj

6 months ago...

CAPRELSA - New Product Releases - MPR

empr.com — “Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on August 5, 2011 at 3:04 pm By:

eMPR MPR Medical Publisher

MPR News: CAPRELSA: Vandetanib 100mg, 300mg, tabs. http://bit.ly/qM5dba

9 months ago...

Symposier - Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance

symposier.com — “Uploaded and shared in Youtube by: mdandersonorg — In April, the U.S. Food and Drug Administration approved the use of vandetanib for the treatment of medullary thyroid carcinoma. MD Anderson's Dr. Robert Gagel who with his team helped to bring about the FDA's approval of vandetanib talks about the drug, the research and it's benefit to medullary thyroid cancer patients.View full resource at symposier.com

  • View Related
  • Share

Most Recently Shared on May 25, 2011 at 3:25 pm By:

SympoEndocrino Symposier Endocrino Health Site

Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance. http://bit.ly/mbMIhJ

11 months ago...

Vandetanib Available for Advanced Medullary Thyroid Cancer - ONA

oncologynurseadvisor.com — “AstraZeneca has made available vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on April 25, 2011 at 7:05 pm By:

Vandetanib Available for Advanced Medullary Thyroid Cancer - MPR

empr.com — “AstraZeneca has made available vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 25, 2011 at 2:19 pm By:

eMPR MPR Medical Publisher

MPR News: Vandetanib Available for Advanced Medullary Thyroid Cancer: AstraZeneca has made available vandetanib ... http://bit.ly/hxrm59

12 months ago...

FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer

drugs.com — “Vandetanib is used to treat advanced medullary thyroid cancer. Includes vandetanib side effects, interactions and indications.View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on April 11, 2011 at 12:50 am By:

drugscom Drugs.com Health Site

FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer - http://bit.ly/hiHKy2

1 year ago...

FDA Approves Orphan Drug Vandetanib For Advanced Medullary Thyroid Cancer

medicalnewstoday.com — “AstraZeneca (NYSE: AZN) has announced that the U.S. Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by sView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on April 8, 2011 at 9:05 am By:

NatureRevEndo NatureRevEndocrinol Endocrinology and Medical Journal

RT @mnt_endocrine: FDA Approves Orphan Drug Vandetanib For Advanced Medullary Thyroid Cancer http://mnt.to/3Tpj #endocrinology

1 year ago...

FDA Approves Vandetanib For Medullary Thyroid Cancer

medicalnewstoday.com — “Vandetanib has been approved by the FDA (Food and Drug Administration) for the treatment of late-stage medullary thyroid cancer in adults who cannot have surgery, and whose disease is progressingView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on April 8, 2011 at 12:36 am By:

Ear_Nose_Throat Ear, Nose, and Throat OW Health

FDA Approves Vandetanib For Medullary Thyroid Cancer: Vandetanib has been approved by the FDA (Food and Drug Adm... http://bit.ly/dQWJOu

1 year ago...

FDA Approves Vandetanib for Metastatic Medullary Thyroid Cancer

onclive.com — “The FDA has approved vandetanib for the treatment of unresectable, late-stage, metastatic medullary thyroid cancerView full resource at onclive.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 9:48 pm By:

ONClive Editor Oncology

FDA Approves Vandetanib for Metastatic Medullary Thyroid Cancer http://goo.gl/MtWfZ

1 year ago...

FDA Okays First Treatment for Rare Thyroid Cancer - QualityPoint Technologies

qualitypointtech.net — “WASHINGTON (MedPage Today) -- The FDA has approved vandetanib for treatment of metastatic medullary thyroid cancer in patients with growing or symptomatic disease who are ineligible for surgery.View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 9:00 pm By:

MedicalFeed MedicalFeed Health News Feed

FDA Okays First Treatment for Rare Thyroid Cancer: WASHINGTON (MedPage Today) -- The FDA has approved vandetanib f... http://bit.ly/ftqNvm

1 year ago...

Medical News: FDA Okays First Treatment for Rare Thyroid Cancer - in Public Health & Policy, FDA General from MedPage Today

medpagetoday.com — “WASHINGTON -- The FDA has approved vandetanib for treatment of metastatic medullary thyroid cancer in patients with growing or symptomatic disease who are ineligible for surgery.View full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 8:44 pm By:

MedicalNews Medical News Health News

FDA Okays First Treatment for Rare Thyroid Cancer http://bit.ly/hpX6ZE

1 year ago...

Medical News: FDA Okays First Treatment for Rare Thyroid Cancer - in Public Health & Policy, FDA General from MedPage Today

medpagetoday.com — “WASHINGTON -- The FDA has approved vandetanib for treatment of metastatic medullary thyroid cancer in patients with growing or symptomatic disease who are ineligible for surgery.View full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 8:39 pm By:

MedicalFeed MedicalFeed Health News Feed

FDA Okays First Treatment for Rare Thyroid Cancer: WASHINGTON (MedPage Today) -- The FDA has… http://goo.gl/fb/3BaXg

1 year ago...

FDA Approves Vandetanib For Medullary Thyroid Cancer

medicalnewstoday.com — “Vandetanib has been approved by the FDA (Food and Drug Administration) for the treatment of late-stage medullary thyroid cancer in adults who cannot have surgery, and whose disease is progressingView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 6:05 pm By:

mnt_drugapprov MNT Drug Approvals Health News

FDA Approves Vandetanib For Medullary Thyroid Cancer http://mnt.to/3TmV #regulatory

1 year ago...

Vandetanib Approved for Metastatic Medullary Thyroid Cancer - MPR

empr.com — “The FDA has approved the orphan drug vandetanib (AstraZeneca), a kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 2:19 pm By:

eMPR MPR Medical Publisher

MPR News: Vandetanib Approved for Metastatic Medullary Thyroid Cancer: The FDA has approved the orphan drug vand... http://bit.ly/eF20pY

1 year ago...

Vandetanib Approved for Metastatic Medullary Thyroid Cancer - ONA

oncologynurseadvisor.com — “The FDA has approved the orphan drug vandetanib (AstraZeneca), a kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on April 7, 2011 at 2:14 pm By:

Advertisement